Baseline patient and disease characteristics
| . | All patients (n = 36) . |
|---|---|
| Age (y), median (range) | 59 (34-80) |
| Gender, N (%) | |
| Male | 30 (83) |
| Female | 6 (17) |
| Prior lines of therapy, median (range) | 3 (1-8) |
| Time from initial diagnosis to vemurafenib treatment (y), median (range) | 10.5 (1-33) |
| Prior splenectomy, N (%) | 6 (17) |
| % of hairy cell involvement in BM at study entry, median (range) | 64 (10-100) |
| ANC x 103/mm3, median (range) | 0.8 (0-7.4) |
| Platelet count × 103/mm3, median (range) | 77 (23-238) |
| Hemoglobin g/dL, median (range) | 11.95 (7.6-15.8) |
| . | All patients (n = 36) . |
|---|---|
| Age (y), median (range) | 59 (34-80) |
| Gender, N (%) | |
| Male | 30 (83) |
| Female | 6 (17) |
| Prior lines of therapy, median (range) | 3 (1-8) |
| Time from initial diagnosis to vemurafenib treatment (y), median (range) | 10.5 (1-33) |
| Prior splenectomy, N (%) | 6 (17) |
| % of hairy cell involvement in BM at study entry, median (range) | 64 (10-100) |
| ANC x 103/mm3, median (range) | 0.8 (0-7.4) |
| Platelet count × 103/mm3, median (range) | 77 (23-238) |
| Hemoglobin g/dL, median (range) | 11.95 (7.6-15.8) |